Uroxatral: Targeted Relief for Benign Prostatic Hyperplasia Symptoms
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.74 | $52.17 (0%) | 🛒 Add to cart |
| 60 | $1.42 | $104.33 $85.27 (18%) | 🛒 Add to cart |
| 90 | $1.32 | $156.50 $118.38 (24%) | 🛒 Add to cart |
| 120 | $1.20 | $208.67 $144.46 (31%) | 🛒 Add to cart |
| 180 | $1.10 | $313.00 $198.63 (37%) | 🛒 Add to cart |
| 270 | $1.00 | $469.50 $270.86 (42%) | 🛒 Add to cart |
| 360 | $0.90
Best per pill | $626.00 $325.04 (48%) | 🛒 Add to cart |
Synonyms | |||
Uroxatral (alfuzosin HCl) is a selective alpha-1 adrenergic receptor antagonist specifically formulated for the management of signs and symptoms associated with benign prostatic hyperplasia (BPH). By selectively relaxing smooth muscle in the prostate and bladder neck, it facilitates improved urinary flow and reduces obstruction without significantly affecting blood pressure at therapeutic doses. This medication is designed for long-term use under medical supervision, offering a well-tolerated option for men seeking relief from lower urinary tract symptoms. Its unique extended-release formulation ensures stable plasma concentrations, optimizing efficacy while minimizing peak-related side effects.
Features
- Contains alfuzosin hydrochloride as the active pharmaceutical ingredient
- Available in 10 mg extended-release tablets
- Selective alpha-1 adrenergic receptor blockade
- Once-daily dosing regimen
- Designed for gradual drug release over 24 hours
- FDA-approved for treatment of BPH symptoms
- Manufactured under strict pharmaceutical quality standards
Benefits
- Significantly improves urinary flow rate and reduces residual urine volume
- Decreases frequency and urgency of urination, particularly nocturia
- Redves straining during micturition and improves bladder emptying
- Enhances overall quality of life through symptom relief
- Minimizes impact on blood pressure compared to non-selective alpha-blockers
- Provides consistent 24-hour symptom control with single daily dosing
Common use
Uroxatral is primarily prescribed for the treatment of symptomatic benign prostatic hyperplasia in adult males. It addresses both obstructive symptoms (weak stream, hesitancy, intermittency) and irritative symptoms (frequency, urgency, nocturia) associated with prostate enlargement. The medication is typically used when symptoms are moderate to severe and affecting daily activities or sleep patterns. Treatment is generally long-term, as BPH is a chronic condition, and symptoms typically return upon discontinuation. Uroxatral may be used as monotherapy or in combination with other BPH treatments, such as 5-alpha reductase inhibitors, depending on prostate size and symptom severity.
Dosage and direction
The recommended dosage of Uroxatral is one 10 mg extended-release tablet taken orally once daily, immediately after the same meal each day. Tablets should be swallowed whole and not crushed, chewed, or divided, as this would compromise the extended-release properties. Administration with food is essential to ensure adequate absorption and maintain therapeutic drug levels. Treatment should be initiated under physician supervision, with regular follow-up to assess response and tolerability. Dosage adjustment is not typically required for elderly patients or those with renal impairment, but caution is advised in hepatic impairment. The medication is intended for use only in adult men and should not be used by women or children.
Precautions
Patients should be advised about the potential for dizziness, orthostatic hypotension, and syncope, particularly during initial treatment or dose escalation. Caution is recommended when driving or operating machinery until the individual response is known. Regular monitoring of blood pressure is advised, especially in patients taking antihypertensive medications concurrently. Patients should be screened for other conditions that might cause similar symptoms, including prostate cancer, before initiating therapy. Those with severe renal impairment (creatinine clearance <30 mL/min) or moderate to severe hepatic impairment should use Uroxatral with caution. Patients undergoing cataract surgery should inform their ophthalmologist about alpha-blocker use due to the risk of intraoperative floppy iris syndrome.
Contraindications
Uroxatral is contraindicated in patients with known hypersensitivity to alfuzosin hydrochloride or any component of the formulation. It should not be used in patients with moderate or severe hepatic impairment (Child-Pugh categories B and C) due to significantly increased drug exposure. Concomitant use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, and clarithromycin is contraindicated due to the potential for markedly increased alfuzosin concentrations. The medication is not indicated for use in women, children, or patients with a history of orthostatic hypotension. Those with severe renal impairment (creatinine clearance <30 mL/min) should generally avoid use unless the potential benefits outweigh the risks.
Possible side effects
The most commonly reported adverse reactions include dizziness (6.3%), upper respiratory tract infection (3.2%), headache (3.2%), and fatigue (3.0%). Orthostatic hypotension may occur in approximately 1% of patients, with syncope reported in 0.1-0.3% of cases. Gastrointestinal effects such as abdominal pain, dyspepsia, constipation, and nausea have been reported in 1-2% of patients. Some individuals may experience sexual dysfunction, including decreased libido, ejaculation disorders, or erectile dysfunction. Less common side effects include tachycardia, palpitations, rash, pruritus, and flushing. Most adverse effects are mild to moderate in severity and often diminish with continued therapy.
Drug interaction
Uroxatral is primarily metabolized by CYP3A4 enzymes and should not be co-administered with strong CYP3A4 inhibitors. Concomitant use with other alpha-adrenergic blocking agents may result in additive hypotensive effects and is not recommended. Caution is advised when using Uroxatral with antihypertensive medications, nitrates, or phosphodiesterase-5 inhibitors due to potential additive vasodilatory effects. Moderate CYP3A4 inhibitors (e.g., erythromycin, diltiazem, verapamil) may increase alfuzosin exposure and require closer monitoring. Although not extensively studied, interactions with warfarin and digoxin have been reported with other alpha-blockers, suggesting the need for monitoring when used concomitantly.
Missed dose
If a dose of Uroxatral is missed, it should be taken as soon as remembered on the same day, with food. If the missed dose is not remembered until the next day, the patient should skip the missed dose and resume the regular dosing schedule with the next scheduled dose. Patients should not take a double dose to make up for a missed dose. Maintaining a consistent dosing schedule relative to meals is important for optimal drug absorption and efficacy. If multiple doses are missed, patients should consult their healthcare provider before resuming therapy.
Overdose
In cases of overdose, expected manifestations would primarily relate to excessive alpha-adrenergic blockade, including significant hypotension, dizziness, tachycardia, and possibly syncope. Supportive care should be initiated, including placement of the patient in a supine position with legs elevated to manage hypotension. Vital signs should be monitored closely, and intravenous fluids may be administered if appropriate. Vasopressors may be considered for persistent hypotension, with careful titration to avoid excessive blood pressure elevation. Gastric lavage or activated charcoal may be considered if ingestion was recent, though the extended-release formulation may limit effectiveness. There is no specific antidote for alfuzosin overdose.
Storage
Uroxatral tablets should be stored at controlled room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be kept in its original container with the lid tightly closed to protect from moisture and light. Tablets should not be stored in bathroom cabinets or other areas subject to high humidity. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations or medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Uroxatral is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to medication may vary, and only a physician can determine the appropriate treatment based on a patient’s specific medical condition, history, and concurrent medications. Patients should not initiate, adjust, or discontinue medication without consulting their healthcare provider. The complete prescribing information should be consulted for comprehensive details regarding use, warnings, and precautions.
Reviews
Clinical studies demonstrate that Uroxatral provides significant improvement in IPSS (International Prostate Symptom Score) compared to placebo, with mean reductions of 4-6 points from baseline. Patients report particular satisfaction with reductions in nocturia and improvement in urinary flow. The selective nature of alfuzosin results in generally favorable tolerability, with most patients able to continue long-term therapy. Urologists appreciate the predictable pharmacokinetics and once-daily dosing that supports adherence. While individual experiences vary, the majority of patients experience meaningful symptom relief within 2-4 weeks of initiation, with maximal benefit typically achieved by 8 weeks of continuous therapy.